EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG secures further financial
resources with shareholder loan
15.06.2011 – 17:58
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 15.06.2011 Ad-hoc SYGNIS Pharma AG secures further financial resources with shareholder loan Heidelberg, 15 June 2011 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a subordinated loan agreement for a total amount of EUR 6 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini), with an interest-rate at customary market conditions. As a result this loan, which is payable on demand, secures the financing of SYGNIS´ existing operations, according to the present plans, at least until the end of 2012. The loan is unsecured, bears no expiry date and may be terminated not before 30 September 2012. In this case the loan is to be repaid within a one month period. The loan agreement will be dissolved through dievini´s corresponding participation in a future capital increase with shareholders subscription rights. In addition, instead of requesting a repayment of the loan, dievini is entitled to a repayment by way of a contribution in kind as part of a capital increase with shareholders subscription rights. Alternatively repayment can be made in return for shares by way of a convertible bond programme, which is yet to be agreed upon. Prerequisite for these repayment options are the resolution and execution of a capital increase with shareholders subscription rights or a convertible bond programme as well as the creation of the conditional capital necessary for the second option through decision of SYGNIS´ Annual General Meeting and registration in the commercial register. For further information please contact: |Peter Willinger | |CFO | |Tel: +49 (0) 6221-454 836 | |Email: peter.willinger@sygnis.de | | | ### Disclaimer Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Michael Wolf Telefon: +49 (0) 6221 454 - 745 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English